Tixentamig

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 17:37:25 GMT 2025` Edited by `admin` on `Wed Apr 02 17:37:25 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1\|KAPPA
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	2X6WP45UD6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Tixentamig

Official Name

English

H-gamma1 heavy chain anti-CD3E (1-455) [VH (Homo sapiens IGHV3-73*01 (92.0%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (120), CDR-IMGT [8.10.16] (26-33.51-60.99-114))(1-125) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, 6-G1v14-1 CH2 A1.3, A1

Preferred Name

English

Immunoglobulin G1, bispecific, anti-(human claudin CLDN18.2) (human monoclonal PR007245 single-domain VH-(GGGGS)3-VH fragment) fusion protein with immunoglobulin G1 [5-serine,19-alanine,20-alanine,22-alanine,134-cysteine,151-serine,153-alanine,192-valine

Common Name

English

tixentamig [INN]

Common Name

English

immunoglobulin (H-gamma1_L-kappa)_scFvhh-G1(h-CH2-CH3), anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)] and anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, surfactant associated protein J, SFTPJ) isoform 2], monoclonal antibody, bispecific, trivalent (t

Common Name

English

Code System Code Type Description

CAS

2969220-04-8

Created by admin on Wed Apr 02 17:37:25 GMT 2025 , Edited by admin on Wed Apr 02 17:37:25 GMT 2025

PRIMARY

FDA UNII

2X6WP45UD6

Created by admin on Wed Apr 02 17:37:25 GMT 2025 , Edited by admin on Wed Apr 02 17:37:25 GMT 2025

PRIMARY

INN

13477

Created by admin on Wed Apr 02 17:37:25 GMT 2025 , Edited by admin on Wed Apr 02 17:37:25 GMT 2025

PRIMARY

From	To
3_137	3_196
3_22	3_90
2_375	2_433
2_269	2_329
2_228	3_214
2_152	2_208
2_22	2_98
1_411	1_469
1_393	2_362
1_305	1_365
1_273	2_237
1_270	2_234
1_158	1_232
1_22	1_96

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_341
N	2_305

Related Record Type Details


					O86SW5D7BQ

CLAUDIN 18 SPLICE VARIANT 2

TARGET->LIGAND

Interaction Type:

PRECLINICAL

Amount:


					ZLW14X2D30

CD3

TARGET->LIGAND

Interaction Type:

PRECLINICAL

Amount:

Related Record Type Details


					2X6WP45UD6

Tixentamig

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS	E	Amount:	PIDOLIC ACID	SZB83O1W42
AMINO ACID REMOVAL	[1_491] [2_455]	C-TERMINUS	L		LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL